Since its incorporation in 2020, BullFrog AI Holdings, Inc. has advanced its bfLEAP™ platform to tackle complex biomedical data and drug repositioning, showing nearly 80% annual revenue growth from 2022 through 2025. Despite technological strides and strategic collaborations to leverage failed late-stage drug candidates, the company continues to report substantial operating losses and negative cash flows. BullFrog's limited cash reserves and Nasdaq listing compliance challenges highlight liquidity risks that constrain its runway and underline the critical need for additional funding. Regulatory requirements and competitive dynamics further complicate the roadmap ahead for this emerging digital biopharmaceutical firm.